Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.
Center for Clinical and Translational Research, MaineHealth Institute for Research, Scarborough, ME 04074, USA.
Endocrinol Metab Clin North Am. 2024 Dec;53(4):513-523. doi: 10.1016/j.ecl.2024.08.003. Epub 2024 Sep 26.
In the last decades, novel therapeutics with anabolic bone properties have been developed and are currently used in the management of osteoporosis particularly in patients with high-risk of fragility fractures. These drugs include PTH-Related Analogues, teriparatide and abaloparatide, and the anti-sclerostin agent romosozumab, this latter drug currently approved only in female patients. Their efficacies in preventing fragility fractures are widely demonstrated and their potential serious side effects were progressively downgraded, including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further data are warranted about their efficacy in glucocorticoids-induces osteoporosis and fracture healings.
在过去几十年中，已经开发出具有合成骨特性的新型治疗药物，目前特别在易发生脆性骨折的患者中用于骨质疏松症的治疗。这些药物包括甲状旁腺激素相关肽类似物、特立帕肽和abaloparatide 以及抗硬骨素制剂罗莫佐单抗，后者目前仅批准用于女性患者。这些药物在预防脆性骨折方面的疗效已得到广泛证实，其潜在的严重副作用也逐渐降低，包括特立帕肽使用者的恶性肿瘤风险和罗莫佐单抗使用者的心血管事件。关于它们在糖皮质激素诱导的骨质疏松症和骨折愈合中的疗效还需要进一步的数据。
